BioElectron Technology, the US-based biotechnology firm with expertise on redox biochemistry, has received a huge boost this week. The company has raised $40 million in debt financing.
Solar Capital Partners led this latest financing event, with some participation from Solar Capital’s affiliates. The newly raised funds will be used to fuel and support activities related to its continued development of EPI-743, a pre-NDA state compound that targets inherited mitochondrial disease.
Additionally, the fresh capital will also be used to support its existing clinical and pre-clinical pipeline of redox therapeutics.
|Image Credit: qimono/Pixabay|
Founded in 2005 and based in Mountain View-based, California, BioElectron Technology is a platform biotechnology company with a strong focus on redox biochemistry, which is used to develop the first-in-class therapeutics for today’s healthcare needs. Led by its CEO, Dr. Matthew Klein, BioElectron also developed a discovery platform that leverages its expertise in the biochemistry of a specific set of an enzyme called oxidoreductases. This discovery has resulted in a rich pre-clinical pipeline of molecules targeting pathways critical to central nervous system disease pathology as well as systemic inflammatory disorders.
The Mountain View-based company has received investments from private investors, patient foundations, and venture capital firms. The company also has a strategic partnership with Sumitomo Dainippon Pharma, a Japanese pharmaceutical company based in Osaka, Japan.